Laura Shawver Sells 50,000 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Laura Shawver sold 50,000 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $11.10, for a total value of $555,000.00. Following the completion of the sale, the director now directly owns 210,346 shares in the company, valued at approximately $2,334,840.60. This trade represents a 19.21 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Laura Shawver also recently made the following trade(s):

• On Monday, December 2nd, Laura Shawver sold 97,244 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $13.56, for a total value of $1,318,628.64.
• On Wednesday, December 4th, Laura Shawver sold 14,772 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $13.75, for a total transaction of $203,115.00.

ARS Pharmaceuticals Stock Performance

Shares of ARS Pharmaceuticals stock traded up $0.26 during trading on Tuesday, hitting $11.34. 922,422 shares of the stock traded hands, compared to its average volume of 1,272,206. The stock has a market cap of $1.10 billion, a P/E ratio of -22.24 and a beta of 0.96. The company has a fifty day moving average price of $13.31 and a two-hundred day moving average price of $12.66. ARS Pharmaceuticals, Inc. has a twelve month low of $5.62 and a twelve month high of $18.51.

Wall Street Analysts Forecast Growth

SPRY has been the topic of a number of research reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $30.00 price objective on shares of ARS Pharmaceuticals in a research note on Tuesday, October 8th. Leerink Partners upped their price target on ARS Pharmaceuticals from $21.00 to $25.00 and gave the company an “outperform” rating in a research report on Friday, September 20th. Four investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, ARS Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $24.00.

Hedge Funds Weigh In On ARS Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. nVerses Capital LLC acquired a new position in shares of ARS Pharmaceuticals during the 3rd quarter worth $30,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in ARS Pharmaceuticals by 151.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,419 shares of the company’s stock worth $63,000 after purchasing an additional 4,472 shares in the last quarter. Principal Financial Group Inc. acquired a new position in ARS Pharmaceuticals during the second quarter worth $87,000. J.W. Cole Advisors Inc. raised its holdings in ARS Pharmaceuticals by 10.8% during the second quarter. J.W. Cole Advisors Inc. now owns 15,400 shares of the company’s stock valued at $131,000 after buying an additional 1,500 shares in the last quarter. Finally, Quarry LP acquired a new stake in shares of ARS Pharmaceuticals in the third quarter worth about $174,000. Institutional investors own 68.16% of the company’s stock.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.